An immune response against KSHV is essential to prevent the development of Kaposi’s sarcoma, and includes the following different immune pathways: (i) Natural killer cells by downregulating the expression of MHC type 1 molecules on tumor cells infected with KSHV [197,198], (ii) KSHV-specific CD8 T-cells’ responses, which is lower in HIV-infected patients with Kaposi’s sarcoma compared with those infected with KSHV but without symptoms [199,200]. This evidence concerns the gene CD8A and Kaposi's sarcoma.